Indication
Hematopoietic Cell Transplant
2 clinical trials
3 products
Product
ASP0113Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)Status: Completed, Estimated PCD: 2017-09-28
Product
PlaceboClinical trial
An Open-label, Single-arm Study of Letermovir (LTV) for Prevention of Recurrent CMV Infection in High-risk Hematopoietic Cell Transplant (HCT) RecipientsStatus: Recruiting, Estimated PCD: 2024-07-01
Product
Letermovir